Accepting clocks that tell time poorly: fluid-phase versus standard ELISA autoantibody assays
Liu E, Eisenbarth GS
Associated Clinical Trial(s):
Liu E, Eisenbarth GS (2007). Accepting clocks that tell time poorly: fluid-phase versus standard ELISA autoantibody assays. Clin Immunol, 125(2), 120-6. https://doi.org/10.1016/j.clim.2007.08.005 PMID: 17904423. PMCID: PMC2104491.
Role of autoantibodies in type 1 diabetes
Miao D, Yu L, Eisenbarth GS
Associated Clinical Trial(s):
Miao D, Yu L, Eisenbarth GS (2007). Role of autoantibodies in type 1 diabetes. Front Biosci, 12, 1889-98. https://doi.org/10.2741/2195 PMID: 17127428.
Reduced CD4+ subset and Th1 bias of the human iNKT cells in Type 1 diabetes mellitus
Kis J, Engelmann P, Farkas K, Richman G, Eck S, Lolley J, Jalahej H, Borowiec M, Kent SC, Treszl A, Orban T
Associated Clinical Trial(s):
Kis J, Engelmann P, Farkas K, Richman G, Eck S, Lolley J, Jalahej H, Borowiec M, Kent SC, Treszl A, Orban T (2007). Reduced CD4+ subset and Th1 bias of the human iNKT cells in Type 1 diabetes mellitus. J Leukoc Biol, 81(3), 654-62. https://doi.org/10.1189/jlb.1106654 PMID: 17151140.
Prevalence of autoantibody-negative diabetes is not rare at all ages and increases with older age and obesity
Wang J, Miao D, Babu S, Yu J, Barker J, Klingensmith G, Rewers M, Eisenbarth GS, Yu L
Associated Clinical Trial(s):
Wang J, Miao D, Babu S, Yu J, Barker J, Klingensmith G, Rewers M, Eisenbarth GS, Yu L (2007). Prevalence of autoantibody-negative diabetes is not rare at all ages and increases with older age and obesity. J Clin Endocrinol Metab, 92(1), 88-92. https://doi.org/10.1210/jc.2006-1494 PMID: 17062766.
HLA-DPB1*0402 protects against type 1A diabetes autoimmunity in the highest risk DR3-DQB1*0201/DR4-DQB1*0302 DAISY population
Baschal EE, Aly TA, Babu SR, Fernando MS, Yu L, Miao D, Barriga KJ, Norris JM, Noble JA, Erlich HA, Rewers MJ, Eisenbarth GS
Associated Clinical Trial(s):
Baschal EE, Aly TA, Babu SR, Fernando MS, Yu L, Miao D, Barriga KJ, Norris JM, Noble JA, Erlich HA, Rewers MJ, Eisenbarth GS (2007). HLA-DPB1*0402 protects against type 1A diabetes autoimmunity in the highest risk DR3-DQB1*0201/DR4-DQB1*0302 DAISY population. Diabetes, 56(9), 2405-9. https://doi.org/10.2337/db07-0029 PMID: 17513705.
Allorecognition and the alloresponse: clinical implications
Afzali B, Lechler RI, Hernandez-Fuentes MP
Associated Clinical Trial(s):
Afzali B, Lechler RI, Hernandez-Fuentes MP (2007). Allorecognition and the alloresponse: clinical implications. Tissue Antigens, 69(6), 545-56. https://doi.org/10.1111/j.1399-0039.2007.00834.x PMID: 17498264.
Human CD4+CD25low adaptive T regulatory cells suppress delayed-type hypersensitivity during transplant tolerance
Xu Q, Lee J, Jankowska-Gan E, Schultz J, Roenneburg DA, Haynes LD, Kusaka S, Sollinger HW, Knechtle SJ, VanBuskirk AM, Torrealba JR, Burlingham WJ
Associated Clinical Trial(s):
Xu Q, Lee J, Jankowska-Gan E, Schultz J, Roenneburg DA, Haynes LD, Kusaka S, Sollinger HW, Knechtle SJ, VanBuskirk AM, Torrealba JR, Burlingham WJ (2007). Human CD4+CD25low adaptive T regulatory cells suppress delayed-type hypersensitivity during transplant tolerance. J Immunol, 178(6), 3983-95. https://doi.org/10.4049/jimmunol.178.6.3983 PMID: 17339499.
A robust immunoassay for anti-interferon autoantibodies that is highly specific for patients with autoimmune polyglandular syndrome type 1
Zhang L, Barker JM, Babu S, Su M, Stenerson M, Cheng M, Shum A, Zamir E, Badolato R, Law A, Eisenbarth GS, Anderson MS
Associated Clinical Trial(s):
Zhang L, Barker JM, Babu S, Su M, Stenerson M, Cheng M, Shum A, Zamir E, Badolato R, Law A, Eisenbarth GS, Anderson MS (2007). A robust immunoassay for anti-interferon autoantibodies that is highly specific for patients with autoimmune polyglandular syndrome type 1. Clin Immunol, 125(2), 131-7. https://doi.org/10.1016/j.clim.2007.07.015 PMID: 17825626. PMCID: PMC2080870.
Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding
Klunker S, Saggar LR, Seyfert-Margolis V, Asare AL, Casale TB, Durham SR, Francis JN, Immune Tolerance Network Group
Associated Clinical Trial(s):
Klunker S, Saggar LR, Seyfert-Margolis V, Asare AL, Casale TB, Durham SR, Francis JN, Immune Tolerance Network Group (2007). Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol, 120(3), 688-95. https://doi.org/10.1016/j.jaci.2007.05.034 PMID: 17631952.
Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study
Seyfert-Margolis V, Gisler TD, Asare AL, Wang RS, Dosch HM, Brooks-Worrell B, Eisenbarth GS, Palmer JP, Greenbaum CJ, Gitelman SE, Nepom GT, Bluestone JA, Herold KC
Associated Clinical Trial(s):
Seyfert-Margolis V, Gisler TD, Asare AL, Wang RS, Dosch HM, Brooks-Worrell B, Eisenbarth GS, Palmer JP, Greenbaum CJ, Gitelman SE, Nepom GT, Bluestone JA, Herold KC (2006). Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes, 55(9), 2588-94. https://doi.org/10.2337/db05-1378 PMID: 16936208.
Extreme genetic risk for type 1A diabetes
Aly TA, Ide A, Jahromi MM, Barker JM, Fernando MS, Babu SR, Yu L, Miao D, Erlich HA, Fain PR, Barriga KJ, Norris JM, Rewers MJ, Eisenbarth GS
Associated Clinical Trial(s):
Aly TA, Ide A, Jahromi MM, Barker JM, Fernando MS, Babu SR, Yu L, Miao D, Erlich HA, Fain PR, Barriga KJ, Norris JM, Rewers MJ, Eisenbarth GS (2006). Extreme genetic risk for type 1A diabetes. Proc Natl Acad Sci U S A, 103(38), 14074-9. https://doi.org/10.1073/pnas.0606349103 PMID: 16966600. PMCID: PMC1563993.
Multi-SNP analysis of MHC region: remarkable conservation of HLA-A1-B8-DR3 haplotype
Aly TA, Eller E, Ide A, Gowan K, Babu SR, Erlich HA, Rewers MJ, Eisenbarth GS, Fain PR
Associated Clinical Trial(s):
Aly TA, Eller E, Ide A, Gowan K, Babu SR, Erlich HA, Rewers MJ, Eisenbarth GS, Fain PR (2006). Multi-SNP analysis of MHC region: remarkable conservation of HLA-A1-B8-DR3 haplotype. Diabetes, 55(5), 1265-9. https://doi.org/10.2337/db05-1276 PMID: 16644681.
International trial of the Edmonton protocol for islet transplantation
Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, Secchi A, Brendel MD, Berney T, Brennan DC, Cagliero E, Alejandro R, Ryan EA, DiMercurio B, Morel P, Polonsky KS, Reems JA, Bretzel RG, Bertuzzi F, Froud T, Kandaswamy R, Sutherland DE, Eisenbarth G, Segal M, Preiksaitis J, Korbutt GS, Barton FB, Viviano L, Seyfert-Margolis V, Bluestone J, Lakey JR
Associated Clinical Trial(s):
Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, Secchi A, Brendel MD, Berney T, Brennan DC, Cagliero E, Alejandro R, Ryan EA, DiMercurio B, Morel P, Polonsky KS, Reems JA, Bretzel RG, Bertuzzi F, Froud T, Kandaswamy R, Sutherland DE, Eisenbarth G, Segal M, Preiksaitis J, Korbutt GS, Barton FB, Viviano L, Seyfert-Margolis V, Bluestone J, Lakey JR (2006). International trial of the Edmonton protocol for islet transplantation. N Engl J Med, 355(13), 1318-30. https://doi.org/10.1056/NEJMoa061267 PMID: 17005949.
Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses
Fudaba Y, Spitzer TR, Shaffer J, Kawai T, Fehr T, Delmonico F, Preffer F, Tolkoff-Rubin N, Dey BR, Saidman SL, Kraus A, Bonnefoix T, McAfee S, Power K, Kattleman K, Colvin RB, Sachs DH, Cosimi AB, Sykes M
Associated Clinical Trial(s):
Fudaba Y, Spitzer TR, Shaffer J, Kawai T, Fehr T, Delmonico F, Preffer F, Tolkoff-Rubin N, Dey BR, Saidman SL, Kraus A, Bonnefoix T, McAfee S, Power K, Kattleman K, Colvin RB, Sachs DH, Cosimi AB, Sykes M (2006). Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant, 6(9), 2121-33. https://doi.org/10.1111/j.1600-6143.2006.01434.x PMID: 16796719.
The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses
Shamji MH, Wilcock LK, Wachholz PA, Dearman RJ, Kimber I, Wurtzen PA, Larché M, Durham SR, Francis JN
Associated Clinical Trial(s):
Shamji MH, Wilcock LK, Wachholz PA, Dearman RJ, Kimber I, Wurtzen PA, Larché M, Durham SR, Francis JN (2006). The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods, 317(1-2), 71-9. https://doi.org/10.1016/j.jim.2006.09.004 PMID: 17070537. PMCID: PMC1934503.
Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis
Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R, Li H, Coffman R, Seyfert V, Eiden JJ, Broide D, Immune Tolerance Network Group
Associated Clinical Trial(s):
Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R, Li H, Coffman R, Seyfert V, Eiden JJ, Broide D, Immune Tolerance Network Group (2006). Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med, 355(14), 1445-55. https://doi.org/10.1056/NEJMoa052916 PMID: 17021320.
Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis
Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG, Mokhtarani M, Seyfert-Margolis V, Asare A, Bateman K, Deniz Y, Immune Tolerance Network Group
Associated Clinical Trial(s):
Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG, Mokhtarani M, Seyfert-Margolis V, Asare A, Bateman K, Deniz Y, Immune Tolerance Network Group (2006). Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol, 117(1), 134-40. https://doi.org/10.1016/j.jaci.2005.09.036 PMID: 16387596.
Development of tolerogenic strategies in the clinic
Knechtle SJ
Associated Clinical Trial(s):
Knechtle SJ (2005). Development of tolerogenic strategies in the clinic. Philos Trans R Soc Lond B Biol Sci, 360(1461), 1739-46. https://doi.org/10.1098/rstb.2005.1705 PMID: 16147538. PMCID: PMC1569535.
Functional avidity directs T-cell fate in autoreactive CD4+ T cells
Mallone R, Kochik SA, Reijonen H, Carson B, Ziegler SF, Kwok WW, Nepom GT
Associated Clinical Trial(s):
Mallone R, Kochik SA, Reijonen H, Carson B, Ziegler SF, Kwok WW, Nepom GT (2005). Functional avidity directs T-cell fate in autoreactive CD4+ T cells. Blood, 106(8), 2798-805. https://doi.org/10.1182/blood-2004-12-4848 PMID: 16030184. PMCID: PMC1895305.
Expression of cutaneous lymphocyte-associated antigen and E-selectin ligand by circulating human memory CD4+ T lymphocytes specific for herpes simplex virus type 2
González JC, Kwok WW, Wald A, McClurkan CL, Huang J, Koelle DM
Associated Clinical Trial(s):
González JC, Kwok WW, Wald A, McClurkan CL, Huang J, Koelle DM (2005). Expression of cutaneous lymphocyte-associated antigen and E-selectin ligand by circulating human memory CD4+ T lymphocytes specific for herpes simplex virus type 2. J Infect Dis, 191(2), 243-54. https://doi.org/10.1086/426944 PMID: 15609235. PMCID: PMC1255909.
Clustering of T cell ligands on artificial APC membranes influences T cell activation and protein kinase C theta translocation to the T cell plasma membrane
Giannoni F, Barnett J, Bi K, Samodal R, Lanza P, Marchese P, Billetta R, Vita R, Klein MR, Prakken B, Kwok WW, Sercarz E, Altman A, Albani S
Associated Clinical Trial(s):
Giannoni F, Barnett J, Bi K, Samodal R, Lanza P, Marchese P, Billetta R, Vita R, Klein MR, Prakken B, Kwok WW, Sercarz E, Altman A, Albani S (2005). Clustering of T cell ligands on artificial APC membranes influences T cell activation and protein kinase C theta translocation to the T cell plasma membrane. J Immunol, 174(6), 3204-11. https://doi.org/10.4049/jimmunol.174.6.3204 PMID: 15749850.
Persistence of herpes simplex virus type 2 VP16-specific CD4+ T cells
Danke NA, Koelle DM, Kwok WW
Associated Clinical Trial(s):
Danke NA, Koelle DM, Kwok WW (2005). Persistence of herpes simplex virus type 2 VP16-specific CD4+ T cells. Hum Immunol, 66(7), 777-87. https://doi.org/10.1016/j.humimm.2005.03.007 PMID: 16112025.
Messenger RNA for FOXP3 in the urine of renal-allograft recipients
Muthukumar T, Dadhania D, Ding R, Snopkowski C, Naqvi R, Lee JB, Hartono C, Li B, Sharma VK, Seshan SV, Kapur S, Hancock WW, Schwartz JE, Suthanthiran M
Associated Clinical Trial(s):
Muthukumar T, Dadhania D, Ding R, Snopkowski C, Naqvi R, Lee JB, Hartono C, Li B, Sharma VK, Seshan SV, Kapur S, Hancock WW, Schwartz JE, Suthanthiran M (2005). Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med, 353(22), 2342-51. https://doi.org/10.1056/NEJMoa051907 PMID: 16319383.
Everolimus and basiliximab permit suppression by human CD4+CD25+ cells in vitro
Game DS, Hernandez-Fuentes MP, Lechler RI
Associated Clinical Trial(s):
Game DS, Hernandez-Fuentes MP, Lechler RI (2005). Everolimus and basiliximab permit suppression by human CD4+CD25+ cells in vitro. Am J Transplant, 5(3), 454-64. https://doi.org/10.1111/j.1600-6143.2005.00758.x PMID: 15707399.
Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells
Bunde T, Kirchner A, Hoffmeister B, Habedank D, Hetzer R, Cherepnev G, Proesch S, Reinke P, Volk HD, Lehmkuhl H, Kern F
Associated Clinical Trial(s):
Bunde T, Kirchner A, Hoffmeister B, Habedank D, Hetzer R, Cherepnev G, Proesch S, Reinke P, Volk HD, Lehmkuhl H, Kern F (2005). Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med, 201(7), 1031-6. https://doi.org/10.1084/jem.20042384 PMID: 15795239. PMCID: PMC2213133.
TCR peptide vaccination in multiple sclerosis: boosting a deficient natural regulatory network that may involve TCR-specific CD4+CD25+ Treg cells
Vandenbark AA
Associated Clinical Trial(s):
Vandenbark AA (2005). TCR peptide vaccination in multiple sclerosis: boosting a deficient natural regulatory network that may involve TCR-specific CD4+CD25+ Treg cells. Curr Drug Targets Inflamm Allergy, 4(2), 217-29. https://doi.org/10.2174/1568010053586327 PMID: 15853744.
Congruent effects of estrogen and T-cell receptor peptide therapy on regulatory T cells in EAE and MS
Offner H, Vandenbark AA
Associated Clinical Trial(s):
Offner H, Vandenbark AA (2005). Congruent effects of estrogen and T-cell receptor peptide therapy on regulatory T cells in EAE and MS. Int Rev Immunol, 24(5-6), 447-77. https://doi.org/10.1080/08830180500371462 PMID: 16318990.
Decreased FOXP3 levels in multiple sclerosis patients
Huan J, Culbertson N, Spencer L, Bartholomew R, Burrows GG, Chou YK, Bourdette D, Ziegler SF, Offner H, Vandenbark AA
Associated Clinical Trial(s):
Huan J, Culbertson N, Spencer L, Bartholomew R, Burrows GG, Chou YK, Bourdette D, Ziegler SF, Offner H, Vandenbark AA (2005). Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res, 81(1), 45-52. https://doi.org/10.1002/jnr.20522 PMID: 15952173.
A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis
Bourdette DN, Edmonds E, Smith C, Bowen JD, Guttmann CR, Nagy ZP, Simon J, Whitham R, Lovera J, Yadav V, Mass M, Spencer L, Culbertson N, Bartholomew RM, Theofan G, Milano J, Offner H, Vandenbark AA
Associated Clinical Trial(s):
Bourdette DN, Edmonds E, Smith C, Bowen JD, Guttmann CR, Nagy ZP, Simon J, Whitham R, Lovera J, Yadav V, Mass M, Spencer L, Culbertson N, Bartholomew RM, Theofan G, Milano J, Offner H, Vandenbark AA (2005). A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis. Mult Scler, 11(5), 552-61. https://doi.org/10.1191/1352458505ms1225oa PMID: 16193893.
Clinical features of children with screening-identified evidence of celiac disease
Hoffenberg EJ, Emery LM, Barriga KJ, Bao F, Taylor J, Eisenbarth GS, Haas JE, Sokol RJ, Taki I, Norris JM, Rewers M
Associated Clinical Trial(s):
Hoffenberg EJ, Emery LM, Barriga KJ, Bao F, Taylor J, Eisenbarth GS, Haas JE, Sokol RJ, Taki I, Norris JM, Rewers M (2004). Clinical features of children with screening-identified evidence of celiac disease. Pediatrics, 113(5), 1254-9. https://doi.org/10.1542/peds.113.5.1254 PMID: 15121938.
